Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was MXN170,322 Mil.
Regeneron Pharmaceuticals's quarterly Total Liabilities
declined
from Sep. 2025 (MXN168,979.43 Mil) to Dec. 2025 (MXN167,485.42 Mil) but then
increased
from Dec. 2025 (MXN167,485.42 Mil) to Mar. 2026 (MXN170,322.46 Mil).
Regeneron Pharmaceuticals's annual Total Liabilities
increased
from Dec. 2023 (MXN120,637.68 Mil) to Dec. 2024 (MXN175,308.84 Mil) but then
declined
from Dec. 2024 (MXN175,308.84 Mil) to Dec. 2025 (MXN167,485.42 Mil).
Regeneron Pharmaceuticals Total Liabilities Related Terms
Regeneron Pharmaceuticals Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Regeneron Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of MXN170,322 Mil mean?
Regeneron Pharmaceuticals (MEX:REGN) has a Total Liabilities of MXN170,322 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Total Liabilities too high?
Regeneron Pharmaceuticals' current Total Liabilities is MXN170,322 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Total Liabilities compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Total Liabilities of MXN170,322 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Total Liabilities is MXN170,322 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (MEX:REGN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN14,585.02, compared to a current price of MXN10,835.99 — trading 25.7% below its estimated fair value. The current Total Liabilities is MXN170,322 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Regeneron Pharmaceuticals (MEX:REGN), the current Total Liabilities is MXN170,322 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (MEX:REGN) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN10,835.99 is trading 25.7% below its estimated GF Value™ of MXN14,585.02.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for MEX:REGN:
Total Liabilities: MXN170,322 Mil
GF Value™: MXN14,585.02 vs. price of MXN10,835.99 (25.7% below fair value)
No single metric tells the full story. See the MEX:REGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score
Get the complete analysis for MEX:REGN
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:REGN has been successfully added to your 
